Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Leqvio on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Switzerland
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Leqvio (inclisiran) is a small interfering RNA (siRNA) therapy approved by the FDA as an adjunct to diet and exercise to reduce LDL cholesterol (LDL-C) in adults with hypercholesterolemia, including adults and pediatric patients 12 years and older with heterozygous familial hypercholesterolemia (HeFH), and in pediatric patients 12 years and older with homozygous familial hypercholesterolemia (HoFH).
Leqvio works by silencing the gene that produces PCSK9, a protein that normally reduces the liver's ability to clear LDL cholesterol from the blood. By reducing PCSK9 production, Leqvio allows the liver to remove more LDL cholesterol from circulation, lowering LDL-C levels for an extended period between doses.
Leqvio is intended for adults with elevated LDL-C who require additional lowering beyond diet, exercise, and other lipid-lowering therapies, as well as adolescents 12 years and older with familial hypercholesterolemia under specialist supervision.
Leqvio is given as a 284 mg subcutaneous injection administered by a healthcare professional, with an initial dose, a second dose at 3 months, and subsequent doses every 6 months thereafter.
Leqvio does not carry a formal FDA boxed warning. However, patients and caregivers should be aware of the following important safety information.
Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with Leqvio. Leqvio is contraindicated in patients with a history of a serious hypersensitivity reaction to inclisiran or any of its excipients.
Injection site reactions, including pain, erythema, and rash, are among the most commonly reported adverse effects and are usually mild to moderate and self-limiting.
Leqvio is intended for use alongside diet, exercise, and other lipid-lowering therapies where needed. It should not be used as a substitute for statins in patients who can tolerate them, unless directed otherwise by a treating physician.
Lipid levels should be monitored periodically to assess response to therapy, particularly around the time of subsequent doses.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Leqvio is manufactured and marketed globally by Novartis Pharmaceuticals. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating cardiologist or lipid specialist confirming diagnosis and prior lipid-lowering therapy history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for cholesterol management, Leqvio is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Leqvio directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Leqvio should be stored at controlled room temperature, 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Leqvio through NPP's regulated import pathway, with cardiology and lipid-management specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support cardiology care coordination and documentation for Leqvio access.
Delhi's major hospitals assist patients with prescription support and documentation for Leqvio.
Bangalore's specialist network offers access coordination for eligible patients seeking Leqvio.
Chennai-based cardiology specialists coordinate Leqvio access alongside comprehensive lipid management.
Hyderabad's care institutions support patients pursuing Leqvio therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Leqvio.
Pune-based specialists assist with prescription support and Leqvio treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Leqvio.
Kochi's specialist units assist patients with the documentation needed for Leqvio access.
Chandigarh's care centers support Leqvio treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Leqvio access process.
Lucknow-based centers assist patients pursuing Leqvio therapy.
Bhubaneswar's institutions support access to Leqvio for eligible patients.
Guwahati's specialists help coordinate Leqvio access for patients across the Northeast.
Patients in other cities across India can also access Leqvio through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
